Highlights Enveric Biosciences, Inc.

Equities

ENVB

US29405E2081

Real-time Estimate Cboe BZX Other stock markets 03:40:08 2024-05-21 pm EDT			5-day change	1st Jan Change
0.824 ^USD	+0.32%		+0.96%	-36.28%

May. 14	Firefly Neuroscience Names David Johnson Executive Chairman, Following WaveDancer Merger	MT
May. 14	Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with Mindbio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Firefly Neuroscience Names David Johnson Executive Chairman, Following WaveDancer Merger	May. 14	MT
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with Mindbio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders	May. 14	CI
Enveric Biosciences, Inc. Announces Signing of Non-Binding Term Sheet with Undisclosed License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids	May. 08	CI
Enveric Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Sector Update: Health Care Stocks Rise Late Afternoon	Mar. 19	MT
Sector Update: Health Care Stocks Higher in Tuesday Afternoon Trading	Mar. 19	MT
Enveric Biosciences Signs Licensing Term Sheets for Joint Disease Treatment Compounds; Shares Rise	Mar. 19	MT
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease	Mar. 19	CI
Enveric Biosciences Surging on Plans to Sell Cannabinoid IP Portfolio, Focus Shift to Psilocin Therapies	Feb. 23	MT
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders	Feb. 21	CI
Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series	Jan. 03	CI
Health Care Up on Defensive Bias -- Health Care Roundup	Dec. 28	DJ
Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series	Dec. 28	CI
Enveric Biosciences Selects Development Candidates from Evm301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds	Dec. 05	CI
Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry	Nov. 27	CI
Enveric Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373	23-10-18	CI
Enveric Biosciences Secures US Patent for EB-373 for Anxiety Disorder Treatment	23-08-28	MT
Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program	23-08-21	CI
Enveric Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Enveric Biosciences, Inc.

Equities

ENVB

US29405E2081

Highlights

Filters